Successful Depressor Effect Concomitant with Complete Normalization of High Renin and Aldosterone Profile by Percutaneous Transluminal Renal Angioplasty in a Patient with Acute Exacerbated Heart Failure with Preserved Ejection Fraction.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
16 Nov 2019
16 Nov 2019
Historique:
entrez:
17
11
2019
pubmed:
17
11
2019
medline:
25
4
2020
Statut:
epublish
Résumé
BACKGROUND Although the effect of percutaneous transluminal renal angioplasty (PTRA) on clinical outcomes has not been established in previous clinical studies, some case reports showed that PTRA drastically improved patient outcomes. The appropriateness of PTRA should be discussed in detail. CASE REPORT A 59-year-old man had been on treatment for hypertension for 5 years, but his blood pressure (BP) had been poorly controlled for the past 5 months. He was hospitalized for pulmonary edema due to heart failure with preserved ejection fraction (HFpEF). During hospitalization, ultrasound and plain computed tomography revealed atrophy of the right kidney, and laboratory investigations indicated secondary aldosteronism with high plasma renin activity (PRA). Unenhanced magnetic resonance imaging (MRI) suggested severe stenosis or occlusion of the right renal artery. PTRA was performed for total occlusion at the origin of the right renal artery, resulting in favorable dilation of the vessel and good blood flow. A differential renal vein renin assay showed a right-left difference of PRA before PTRA, but this disappeared after the procedure. Both PRA and the plasma aldosterone concentration were normalized after PTRA. In addition, the patient's BP decreased, proteinuria was reduced, diuretics could be discontinued, and his calcium channel blocker dosage was decreased. CONCLUSIONS The present case suggests that screening for renal artery stenosis by unenhanced MRI may be useful in patients who have HFpEF because PTRA can be used to achieve marked improvement of hypertension, endocrine abnormalities, and heart failure if stenosis is detected.
Identifiants
pubmed: 31732710
pii: 917973
doi: 10.12659/AJCR.917973
pmc: PMC6878965
doi:
Substances chimiques
Aldosterone
4964P6T9RB
Renin
EC 3.4.23.15
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1684-1690Références
Circ J. 2007 Dec;71(12):1942-7
pubmed: 18037751
Int Urol Nephrol. 2019 Feb;51(2):285-291
pubmed: 30607776
N Engl J Med. 2009 Nov 12;361(20):1953-62
pubmed: 19907042
J Am Coll Cardiol. 2006 Jan 3;47(1):76-84
pubmed: 16386668
J Vasc Interv Radiol. 2002 Dec;13(12):1187-98
pubmed: 12471181
Am J Cardiol. 2007 Jul 15;100(2):273-9
pubmed: 17631082
Kidney Res Clin Pract. 2019 Sep 30;38(3):336-346
pubmed: 31234613
Catheter Cardiovasc Interv. 2006 Aug;68(2):311-8
pubmed: 16819778
AJR Am J Roentgenol. 2012 Nov;199(5):W629-37
pubmed: 23096208
Clin Sci (Lond). 1997 Nov;93(5):435-43
pubmed: 9486089
Lancet. 1998 Jul 4;352(9121):13-6
pubmed: 9800739
QJM. 1999 Mar;92(3):159-67
pubmed: 10326075
Am J Kidney Dis. 2014 Feb;63(2):186-97
pubmed: 24074824
J Am Coll Cardiol. 2012 Mar 13;59(11):998-1005
pubmed: 22402071
J Am Coll Cardiol. 2007 Sep 11;50(11):1015-20
pubmed: 17825709
N Engl J Med. 2014 Jan 2;370(1):13-22
pubmed: 24245566
Eur J Radiol Open. 2016 Aug 04;3:200-6
pubmed: 27536710